JP2006502159A - 認知障害を予防するための向精神性のないカンナビノイド - Google Patents

認知障害を予防するための向精神性のないカンナビノイド Download PDF

Info

Publication number
JP2006502159A
JP2006502159A JP2004534012A JP2004534012A JP2006502159A JP 2006502159 A JP2006502159 A JP 2006502159A JP 2004534012 A JP2004534012 A JP 2004534012A JP 2004534012 A JP2004534012 A JP 2004534012A JP 2006502159 A JP2006502159 A JP 2006502159A
Authority
JP
Japan
Prior art keywords
saturated
unsaturated
branched
cyclic
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2004534012A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006502159A5 (https=
Inventor
キンドラー、セス
ガルゾン、アーロン
フィンク、ジョージ
Original Assignee
ファーモス コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IL2003/000604 external-priority patent/WO2004023340A2/en
Application filed by ファーモス コーポレイション filed Critical ファーモス コーポレイション
Publication of JP2006502159A publication Critical patent/JP2006502159A/ja
Publication of JP2006502159A5 publication Critical patent/JP2006502159A5/ja
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2004534012A 2002-09-05 2003-09-04 認知障害を予防するための向精神性のないカンナビノイド Abandoned JP2006502159A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40895802P 2002-09-05 2002-09-05
PCT/IL2003/000604 WO2004023340A2 (en) 2002-09-05 2003-07-23 Non-psychotropic cannabinoids for prevention of cognitive impairment
PCT/IL2003/000735 WO2004021974A2 (en) 2002-09-05 2003-09-04 Non-psychotropic cannabinoids for prevention of cognitive impairment

Publications (2)

Publication Number Publication Date
JP2006502159A true JP2006502159A (ja) 2006-01-19
JP2006502159A5 JP2006502159A5 (https=) 2006-10-19

Family

ID=31980345

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004534012A Abandoned JP2006502159A (ja) 2002-09-05 2003-09-04 認知障害を予防するための向精神性のないカンナビノイド

Country Status (3)

Country Link
JP (1) JP2006502159A (https=)
AU (1) AU2003256059A1 (https=)
WO (1) WO2004021974A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024504116A (ja) * 2021-01-15 2024-01-30 ケンブリッジ コグニション リミテッド 周術期神経認知障害及び／又はウイルス感染後認知障害の個人を特定する方法及びシステム

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060025448A1 (en) 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521215A (en) * 1989-11-07 1996-05-28 Ramot University Authority For Applied Research And Industrial Development Ltd. NMDA-blocking pharmaceuticals
US5284867A (en) * 1989-11-07 1994-02-08 Yissum Research Development Company Of The Hebrew University In Jerusalem NMDA-blocking pharmaceutical compositions
US6096740A (en) * 1990-11-06 2000-08-01 Ramot University Authority For Applied Research And Industrial Development Ltd. Dexanabinol derivatives and their use as neuroprotective pharmaceutical compositions
US6211230B1 (en) * 1999-09-27 2001-04-03 The United States Of America As Represented By The Secretary Of The Army Method of reducing brain damage resulting from seizures

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024504116A (ja) * 2021-01-15 2024-01-30 ケンブリッジ コグニション リミテッド 周術期神経認知障害及び／又はウイルス感染後認知障害の個人を特定する方法及びシステム

Also Published As

Publication number Publication date
WO2004021974A2 (en) 2004-03-18
WO2004021974A3 (en) 2004-05-06
AU2003256059A1 (en) 2004-03-29

Similar Documents

Publication Publication Date Title
US8343947B2 (en) Therapeutic treatment
US10925890B2 (en) Use of dextran sulfate
CN104270945A (zh) App特异性bace抑制剂(asbi)及其用途
JP6708869B2 (ja) 神経系疾患治療剤
RU2336870C2 (ru) Применение l-бутилфталида для изготовления лекарственного средства для профилактики и лечения церебрального инфаркта
US20020077355A1 (en) Use of epoxyeicosatrienoic acids in the treatment of cerebrovascular conditions
JPH115738A (ja) 脳虚血に伴う神経脱落症状の予防剤および超急性期治療剤
JP2006502159A (ja) 認知障害を予防するための向精神性のないカンナビノイド
US20060160896A1 (en) Therapeutic treatment
JP6271539B2 (ja) バクロフェン及びアカンプロセートに基づいた黄斑変性疾患の治療法
JP5469707B2 (ja) 脳梗塞に関連する脳血管障害の治療に有用なピラゾロン化合物
KR20120038982A (ko) 노령 및 신장 손상 ｓｔ 비상승 심근 경색 환자의 치료를 위한 오타믹사반
JP5263548B2 (ja) イブジラストを有効成分とする脳動脈瘤の予防、形成抑制又は治療剤
US9333207B2 (en) Pharmaceutical composition of 1-adamantylethyloxy-3-morpholino-2-propanol or pharmaceutically acceptable salts thereof for the treatment of cerebrovascular disease and neurodegenerative diseases of the central nervous system
JP2024525998A (ja) 脳梗塞治療用医薬組成物
US20050192341A1 (en) Non-psychotropic cannabinoids for prevention of cognitive impairment
WO2023065071A1 (zh) 莰醇在制备治疗缺血性脑卒中的药物中的用途
CN103917544A (zh) 氯吡格雷的分阶段给药
WO2004023340A2 (en) Non-psychotropic cannabinoids for prevention of cognitive impairment
RU2506950C2 (ru) Комбинация карбостирила и карнитина
JP2002154985A (ja) 眼疾患治療剤
WO2025135087A1 (ja) 慢性移植片対宿主病における眼合併症の予防治療用医薬組成物
JPH0256327B2 (https=)
SE538144C2 (sv) Use of dextran sulfate for inducing angiogenesis
JPH03848B2 (https=)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060901

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060901

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20080307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080307